tradingkey.logo

BioLine RX Ltd

BLRX
3.730USD
+0.060+1.57%
Close 10/17, 16:00ETQuotes delayed by 15 min
9.54BMarket Cap
LossP/E TTM

BioLine RX Ltd

3.730
+0.060+1.57%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of BioLine RX Ltd

Currency: USD Updated: 2025-10-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioLine RX Ltd's Score

Industry at a Glance

Industry Ranking
148 / 501
Overall Ranking
265 / 4691
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
26.000
Target Price
+597.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BioLine RX Ltd Highlights

StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.94M.
Overvalued
The company’s latest PE is -0.89, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 66.21K shares, decreasing 43.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-17

The company's current financial score is 6.90, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 304.00K, representing a year-over-year decrease of 94.36%, while its net profit experienced a year-over-year decrease of 914.05%.

Score

Industry at a Glance

Previous score
6.90
Change
0

Financials

5.37

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.56

Operational Efficiency

10.00

Growth Potential

5.34

Shareholder Returns

7.23

BioLine RX Ltd's Company Valuation

Currency: USD Updated: 2025-10-17

The company’s current valuation score is 7.46, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.89, which is 0.00% below the recent high of -0.89 and -228455.58% above the recent low of -2032.77.

Score

Industry at a Glance

Previous score
7.46
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 148/501
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-17

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for BioLine RX Ltd is 26.00, with a high of 40.00 and a low of 12.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
26.000
Target Price
+597.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

551
Total
5
Median
6
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
2
CRISPR Therapeutics AG
CRSP
30
Ionis Pharmaceuticals Inc
IONS
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
1
2
3
...
110

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-17

The company’s current price momentum score is 5.49, which is lower than the Biotechnology & Medical Research industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 4.34 and the support level at 3.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
5.61
Change
-0.12

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.072
Neutral
RSI(14)
43.879
Neutral
STOCH(KDJ)(9,3,3)
11.793
Oversold
ATR(14)
0.339
Low Volatility
CCI(14)
-93.490
Neutral
Williams %R
83.838
Oversold
TRIX(12,20)
0.206
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
3.852
Sell
MA10
4.041
Sell
MA20
3.937
Sell
MA50
3.832
Sell
MA100
4.171
Sell
MA200
3.941
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-17

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 1.52%, representing a quarter-over-quarter decrease of 67.15%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Hong Seng Technology Ltd
170.73K
--
Citadel Advisors LLC
14.95K
--
Simplex Trading, LLC
14.11K
--
Two Sigma Investments, LP
13.82K
--
Susquehanna International Group, LLP
11.10K
--
Rhumbline Advisers Ltd. Partnership
4.28K
+179.41%
Citi Investment Research (US)
4.00K
--
Intracoastal Capital, L.L.C.
3.13K
--
Wells Fargo Advisors
1.75K
-41.67%
Morgan Stanley Smith Barney LLC
900.00
--
1
2

Risk Assessment

Currency: USD Updated: 2025-10-17

The company’s current risk assessment score is 2.66, which is lower than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.66
Change
0
Beta vs S&P 500 index
1.33
VaR
+7.22%
240-Day Maximum Drawdown
+88.86%
240-Day Volatility
+136.23%

Return

Best Daily Return
60 days
+16.16%
120 days
+38.50%
5 years
+52.98%
Worst Daily Return
60 days
-7.18%
120 days
-21.90%
5 years
-40.87%
Sharpe Ratio
60 days
-1.05
120 days
+0.76
5 years
-0.31

Risk Assessment

Maximum Drawdown
240 days
+88.86%
3 years
+97.52%
5 years
+98.76%
Return-to-Drawdown Ratio
240 days
-0.87
3 years
-0.30
5 years
-0.19
Skewness
240 days
-0.80
3 years
-0.28
5 years
+0.34

Volatility

Realised Volatility
240 days
+136.23%
5 years
+105.21%
Standardised True Range
240 days
+15.69%
5 years
+107.01%
Downside Risk-Adjusted Return
120 days
+140.08%
240 days
+140.08%
Maximum Daily Upside Volatility
60 days
+57.62%
Maximum Daily Downside Volatility
60 days
+45.38%

Liquidity

Average Turnover Rate
60 days
+0.01%
120 days
+0.03%
5 years
--
Turnover Deviation
20 days
-97.33%
60 days
-93.56%
120 days
-68.42%

Peer Comparison

Biotechnology & Medical Research
BioLine RX Ltd
BioLine RX Ltd
BLRX
6.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Qiagen NV
Qiagen NV
QGEN
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
Ascendis Pharma A/S
ASND
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
Alkermes Plc
ALKS
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insmed Inc
Insmed Inc
INSM
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI